Mike Kratky
Stock Analyst at Leerink Partners
(3.33)
# 984
Out of 5,165 analysts
38
Total ratings
43.48%
Success rate
25.57%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Maintains: Outperform | $55 → $30 | $27.36 | +9.65% | 2 | Feb 26, 2026 | |
| PODD Insulet | Maintains: Outperform | $386 → $360 | $230.49 | +56.19% | 2 | Feb 19, 2026 | |
| TXG 10x Genomics | Maintains: Market Perform | $22 → $20 | $18.09 | +10.56% | 5 | Jan 27, 2026 | |
| PEN Penumbra | Downgrades: Market Perform | $374 | $338.00 | +10.65% | 2 | Jan 16, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $127 → $128 | $71.20 | +79.78% | 2 | Oct 1, 2025 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $55.15 | +75.88% | 7 | Aug 15, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $88.44 | +24.38% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $10.64 | +163.16% | 1 | Feb 24, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $67.32 | +29.23% | 2 | Oct 25, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $23.91 | +88.21% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $13.82 | +59.19% | 1 | Jan 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $32.50 | +29.23% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $482.76 | -29.16% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $84.27 | -11.00% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $32.75 | -72.52% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.33 | +3,283.46% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $443.18 | -28.92% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $81.21 | -61.83% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $25.10 | -44.22% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $28.60 | +39.86% | 1 | Aug 15, 2022 |
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Outperform
Price Target: $55 → $30
Current: $27.36
Upside: +9.65%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $386 → $360
Current: $230.49
Upside: +56.19%
10x Genomics
Jan 27, 2026
Maintains: Market Perform
Price Target: $22 → $20
Current: $18.09
Upside: +10.56%
Penumbra
Jan 16, 2026
Downgrades: Market Perform
Price Target: $374
Current: $338.00
Upside: +10.65%
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $127 → $128
Current: $71.20
Upside: +79.78%
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $55.15
Upside: +75.88%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $88.44
Upside: +24.38%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $10.64
Upside: +163.16%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $67.32
Upside: +29.23%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $23.91
Upside: +88.21%
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $13.82
Upside: +59.19%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $32.50
Upside: +29.23%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $482.76
Upside: -29.16%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $84.27
Upside: -11.00%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $32.75
Upside: -72.52%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.33
Upside: +3,283.46%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $443.18
Upside: -28.92%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $81.21
Upside: -61.83%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $25.10
Upside: -44.22%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $28.60
Upside: +39.86%